Butaneamide, N,3-dimethyl-2-methylene-

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Butaneamide, N,3-dimethyl-2-methylene-
• 英文别名: N,3-dimethyl-2-methylidenebutanamide
• 化学式: C₇H₁₃NO
• 分子量: 127.18
• InChiKey: DTZBBIVCHZLRAY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• Methods of promoting wound healing using CRM1 inhibitors
  申请人：Karyopharm Therapeutics Inc.

  公开号：US10202366B2

  公开（公告）日：2019-02-12

  The invention generally relates to the use of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula I: or a pharmaceutically acceptable salt thereof, wherein Ring A, X, R1, R2 and n are as defined and described herein, in a method for promoting wound healing in a subject.

  本发明一般涉及核转运调节剂（如 CRM1 抑制剂）的使用，特别是结构式 I 所代表的化合物： 或其药学上可接受的盐，其中环 A、X、R1、R2 和 n 如本文所定义和描述，用于促进受试者伤口愈合的方法。
• HYDROGEL COMPOSITIONS BONDED TO POLYMERIC SUBSTRATES
  申请人：3M Innovative Properties Company

  公开号：EP3356485A1

  公开（公告）日：2018-08-08
• SYSTEMS AND METHODS FOR BISTABLE OLIGOMERIC MACHINES
  申请人：Avetisov, Vladik

  公开号：EP3947492A2

  公开（公告）日：2022-02-09
• Novel process for the preparation of cyclosporin derivatives
  申请人：Viskov Christian

  公开号：US20070213260A1

  公开（公告）日：2007-09-13

  The invention concerns a novel method for preparing an intermediate polyanion for preparing cyclosporin derivatives by treating a cyclosporin with a hexamethyldisilazane metal salt, optionally in the presence of a metal halide. The treated cyclosporin has one or several free hydroxy groups and/or non-methylated nitrogen atoms in position a and/or any other acid group capable of deprotonation which are optionally deprotonated or in protected form.
• NOVEL PROCESS FOR THE PREPARATION OF CYCLOSPORIN DERIVATIVES
  申请人：VISKOV Christian

  公开号：US20100173838A1

  公开（公告）日：2010-07-08

  The invention concerns a novel method for preparing an intermediate polyanion for preparing cyclosporin derivatives by treating a cyclosporin with a hexamethyldisilazane metal salt, optionally in the presence of a metal halide. The treated cyclosporin has one or several free hydroxy groups and/or non-methylated nitrogen atoms in position α and/or any other acid group capable of deprotonation which are optionally deprotonated or in protected form.